Quest Diagnostics Incorporated (DGX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Quest Diagnostics Incorporated (DGX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How DGX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | 33.2% | 14.1% | $992.0M | $1.36B | 10.3% |
| FY 2024 | $9.87B | 32.9% | 13.6% | $871.0M | $909.0M | 9% |
| FY 2023 | $9.25B | 44% | 13.6% | $854.0M | $855.7M | 10.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring DGX)
- ✓Live walkthrough of DGX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
DGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DGX. Explore sector supply chains on /butterfly.
DGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Quest Diagnostics Incorporated (DGX)?
In FY 2025 (10-K), DGX converted $11.0B of revenue into a 33.2% gross margin, 14.1% operating margin, and $1.4B in free cash flow (12.3% FCF margin).